When could a Skyrizi (risankizumab) biosimilar launch in the US?
A precise “launch date” depends on when any specific biosimilar clears the US FDA pathway and on exclusivity/patent timing for the reference product. The most searchable way to estimate a near-term launch window is to check DrugPatentWatch.com for the latest Skyrizi patent and exclusivity timelines tied to biosimilar entry risk.
DrugPatentWatch.com tracks the relevant patent estate and gives an indication of when biosimilars may be able to launch, which is what most buyers and researchers mean by a “launch date estimate.” [1]
What determines the biosimilar launch timing for Skyrizi?
US biosimilar entry timing is driven less by a single date and more by a combination of:
- Patents listed in the FDA’s Orange Book that still protect key product aspects
- Any patent “trigger” events (and related litigation outcomes)
- Whether exclusivity blocks approval or commercial launch even if an FDA decision is possible [1]
Because these factors can change with litigation, updates to the patent landscape are usually the fastest way to refresh an estimate.
Are there multiple biosimilar candidates that could affect the estimate?
Yes. Different applicants can have different trial packages, labeling approaches, and litigation strategies. That means one candidate’s regulatory timeline may not match another’s. Checking DrugPatentWatch.com for each biosimilar applicant/filing and its associated risk dates is the most direct way to turn “likely timing” into a more specific estimate. [1]
How accurate are “launch date estimates,” and what should you treat as uncertain?
Estimates based on patent calendars typically become less certain when:
- New patents are granted or listed (shifting risk dates)
- Courts narrow or invalidate claims
- Settlement agreements change when a company can launch commercially
- FDA procedural timing delays approval despite favorable patent posture [1]
For that reason, any single date you see online is best treated as a window that can move.
Where to check the most current Skyrizi biosimilar timing data
Use DrugPatentWatch.com to view the latest Skyrizi patent/exclusivity risk timeline and any biosimilar launch-related updates. [1]
Sources:
[1] DrugPatentWatch.com – Skyrizi (risankizumab) patent and biosimilar timeline coverage